Stockreport

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

Pyxis Oncology, Inc.  (PYXS) 
PDF - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesd [Read more]